The purpose of the study was to carry out the examination of hemic indicators in patients during polytrauma with chronic heart failure without acute myocardium injury using ethylmethylhydroxypyridine succinate. Materials and methods. The study included 96 patients in the polytrauma department. Patients were divided into 3 groups. The first group included 29 patients of the control group (C) aged 58.7±9.4 years. Group C patients showed no signs of chronic heart failure. The second group of standard (S) included 33 patients with the same injuries, but with confirmed chronic heart failure aged 60.0±9.6 years. Group C patients received intensive care according to the local protocol developed in accordance with the protocol of the Ministry of Healthcare of Ukraine. The third group E included 33 patients aged 62.8±8.8 years who received ethylmethylhydroxypyridine succinate during intensive care. Group E patients differed from patients of group S only by receiving ethylmethylhydroxypyridine succinate. Results and discussion. The concentration of hemoglobin of group C patients during admission is 99.9±22.1 g/l, on the 3rd day – 100.3±15.0 g/l, on the 7th day – 111.1±9.2 g/l. The hemoglobin saturation of arterial blood (SaO2) during admission in group C was 0.93±0.03, on the 3rd day – 0.96±0.02 (p <0.001), and on the 7th day – up to 0.97±0.01 (p <0.001). The hemoglobin saturation of venous blood (SvO2): within admission – 0.70±0.04, on the 3rd day – 0.73±0.02 (p <0.001), on the 7th day – 0.77±0.02 (p <0.001). The oxygen tension dissolved in arterial blood (PaO2) during admission of group C patients is 86.9±4.1 mm Hg, on the 3rd day – 89.2±3.2, on the 7th day – 91.6±2.8 mm Hg. The oxygen tension dissolved in venous blood (PvO2) was 37.3±1.2, 38.9±0.7 and 40.0±0.6 mm Hg, according to the stages of the study. The hemoglobin concentration of group S patients was 109.7±23.3 g/l, then decreased to 100.7±10.4 g/l (p <0.05), and on the 7th day – 107.6±10.1 g/l (p >0.1 compared to the initial level). SaO2 during admission of group S was 0.92±0.03, on the 3rd day – 0.95±0.02 (p <0.001), on the 7th day – 0.96±0.03 (p >0.6). SvO2 was 0.68±0.03, 0.72±0.02 (p <0.001) and 0.73±0.03, respectively at the study stages. PaO2 within admission of group C patients amounted to 82.4±3.5, 89.2±3.6 (p <0.001) and 90.4±4.8 mm Hg. PvO2 was 36.8±1.0, 38.5±0.7 and 39.2±1.2 mm Hg in accordance with the research stages. The hemoglobin concentration during admission of group E patients was 110.2±24.6 g/l, on the 3rd day – 100.0±28.8 g/l, on the 7th day – 113.4±27.2 g/l. SaO2 during admission of group E was 0.92±0.03, on the 3rd day – 0.97±0.02 (p <0.001), did not change until the end of the study. SvO2 during admission was 0.68±0.05, on the 3rd day – 0.73±0.02 (p <0.001), on the 7th day – 0.75±0.02 (p <0.04). PaO2 during admission of group E patients was 82.5±3.6 mm Hg, on the 3rd day – 90.3±5.0 mm Hg (p <0.001), on the 7th day 90.9±5.8 mm Hg (p >0.6). The PvO2 dynamics was 36.5±0.6, 39.0±0.6 and 39.1±0.6 mm Hg in accordance with the research stages. Conclusion. Hemoglobin level and blood gas indicators reflect a close relationship with chronic heart failure. Therefore, it is clear that these indicators level tends to increase especially on the 7th day. It can be concluded that ethylmethylhydroxypyridine succinate has a cumulative action

Keywords: polytrauma, chronic heart failure, blood gases, hemoglobin, antioxidants

Full text: PDF (Eng) 262K

1. Authors/Task Force Members: McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022 Jan;24(1):4-131. PMID: 35083827. https://doi.org/10.1002/ejhf.2333
2. Fudim M, Abraham WT, von Bardeleben RS, Lindenfeld J, Ponikowski PP, Salah HM, et al. Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 Aug 31;78(9):931-956. PMID: 34446165. https://doi.org/10.1016/j.jacc.2021.06.040
3. Maitz A, Haussner F, Braumüller S, Hoffmann A, Lupu L, Wachter U, et al. Temporal-spatial organ response after blast-induced experimental blunt abdominal trauma. FASEB J. 2021 Dec;35(12):e22038. PMID: 34748229. https://doi.org/10.1096/fj.202100995R
4. a Kuchcik M. Mortality and thermal environment (UTCI) in Poland-long-term, multi-city study. Int J Biometeorol. 2021 Sep;65(9):1529-1541. PMID: 32880062. PMCID: PMC8370924. https://doi.org/10.1007/s00484-020-01995-w.
5. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. PMID: 34447992. https://doi.org/10.1093/eurheartj/ehab368
6. Song X, Pi R, Zhang Y, Wu J, Dong Y, Zhang H, et al. Determinants and Prediction of Injury Severities in Multi-Vehicle-Involved Crashes. Int J Environ Res Public Health. 2021 May 15;18(10):5271. PMID: 34063528. PMCID: PMC8157156. https://doi.org/10.3390/ijerph18105271
7. Sarang B, Bhandarkar P, Raykar N, O'Reilly GM, Soni KD, Wärnberg MG, et al. Associations of On-arrival Vital Signs with 24-hour In-hospital Mortality in Adult Trauma Patients Admitted to Four Public University Hospitals in Urban India: A Prospective Multi-Centre Cohort Study. Injury. 2021 May;52(5):1158-1163. PMID: 33685640. https://doi.org/10.1016/j.injury.2021.02.075
8. Ioannou LG, Mantzios K, Tsoutsoubi L, Nintou E, Vliora M, Gkiata P, et al. Occupational Heat Stress: Multi-Country Observations and Interventions. Int J Environ Res Public Health. 2021 Jun 10;18(12):6303. PMID: 34200783. PMCID: PMC8296111. https://doi.org/10.3390/ijerph18126303
9. Mesquita T, Lin YN, Ibrahim A. Chronic low-grade inflammation in heart failure with preserved ejection fraction. Aging Cell. 2021 Sep;20(9):e13453. PMID: 34382743. PMCID: PMC8441359. https://doi.org/10.1111/acel.13453
10. Hunt JC, Herrera-Hernandez E, Brandolino A, Jazinski-Chambers K, Maher K, Jackson B, et al. Validation of the Injured Trauma Survivor Screen: An American Association for the Surgery of Trauma multi-institutional trial. J Trauma Acute Care Surg. 2021 May 1;90(5):797-806. PMID: 33797497. https://doi.org/10.1097/TA.0000000000003079
11. Kireev I, Orobets V, Sevostyanova O, Shakhova V, Agarkov A. Prospects of using antioxidant drugs for the treatment and prevention diseases of farm animals. Res J Pharm Biol Chemical Sci. 2018;9(5):2031-6.
12. Sviridova NK. Ishemicheskiy insult i infarkt miokarda: perspektivnye terapevticheskie tseli dlya zashchity mozga i serdtsa [Ischemic stroke and myocardial infarction: prospective therapeutic targets to protect the brain and heart]. East Eur J Neurol. 2018;3(21):26-32. [Russian]. https://doi.org/10.33444/2411-5797.2018.3(21).26-32
13. Mikhnevich KG, Volkova JV, Baranova NV, Boyko EV. Opredelenie referentnykh znacheniy energeticheskikh pokazateley krovoobrashcheniya [Energy indicators reference values determination of blood circulation]. Ukr J Med Biol Sport. 2020;4(26):182-8. [Russian]. https://doi.org/10.26693/jmbs05.04.182
14. Kireev I, Orobets V, Balabekov A, Chukov S. The effect of antioxidants on the microstructure of tissues in the experimental aseptic inflammation focus the experimental aseptic inflammation focus. XII International Scientific Conference on Agricultural Machinery Industry. Earth and Environmental Sci. 2019;403:012085. https://doi.org/10.1088/1755-1315/403/1/012085
15. Nikonov VV, Chernov AL, Feskov AE, Sokolov AS, Beletskiy AV. Vozmozhnosti primeneniya etilmetilgidroksipiridina suktsinata v kompleksnoy intensivnoy terapii ostrogo perioda cherepno-mozgovoy travmy [Possibilities of using ethylmethylhydroxypyridine succinate in complex intensive care of craniocerebral injury acute period]. Int Neurolog J. 2018;7(101):28-33. [Russian]